Literature DB >> 17908966

The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.

Shinichi Toyooka1, Keitaro Matsuo, Hisayuki Shigematsu, Takayuki Kosaka, Masaki Tokumo, Yasushi Yatabe, Syuji Ichihara, Michio Inukai, Hiroshi Suehisa, Junichi Soh, Katsuyuki Kiura, Kwun M Fong, Huei Lee, Ignacio I Wistuba, Adi F Gazdar, Tetsuya Mitsudomi, Hiroshi Date.   

Abstract

PURPOSE: Mutation of epidermal growth factor receptor (EGFR) gene has been reported to be present in non-small cell lung cancer (NSCLC) and significantly associated with female sex and never-smoking status. In this study, we extensively investigated the impact of sex and smoking on the EGFR mutation. EXPERIMENTAL
DESIGN: We examined EGFR exons 18 to 21 status in 1,467 NSCLC patients by direct sequencing to study the impact of sex and smoking status on the EGFR mutational spectrum.
RESULTS: Among 1,467 patients, 197 mutations were found at exon 19, 176 at exon 21, 21 at exon 18, and 24 at exon 20. To examine the independent effect of sex and smoking, the mutational status of each exon was compared between smokers and never smokers in each sex and between males and females stratified by smoking status. In females, exon 19 (P = 0.001) and exon 21 (P < 0.001) mutations were significantly less frequent in ever smokers compared with never smokers. In males, exon 19 (P < 0.001), exon 21 (P < 0.001), and exon 18 (P = 0.003) mutations were significantly less frequent in ever smokers compared with never smokers. In analysis stratified by smoking, there was no difference in sex among never smokers. However, exon 19 mutations were significantly less frequent in males compared with females among ever smokers (P = 0.003). In addition, the interactive effect of male sex and ever smoking status significantly decreased the frequency of exon 19 mutations (P = 0.047) when female never smoker was set as a reference.
CONCLUSION: Both sex and smoking status could influence the EGFR mutational spectrum. Our findings suggest that individual EGFR exons may have differing susceptibilities for mutagenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908966     DOI: 10.1158/1078-0432.CCR-07-0216

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.

Authors:  Daichi Fujimoto; Hiroyuki Ueda; Ryoko Shimizu; Ryoji Kato; Takehiro Otoshi; Takahisa Kawamura; Koji Tamai; Yumi Shibata; Takeshi Matsumoto; Kazuma Nagata; Kyoko Otsuka; Atsushi Nakagawa; Kojiro Otsuka; Nobuyuki Katakami; Keisuke Tomii
Journal:  Clin Exp Metastasis       Date:  2014-03-30       Impact factor: 5.150

Review 2.  Lung cancer early detection and health disparities: the intersection of epigenetics and ethnicity.

Authors:  Lane Lerner; Robert Winn; Alicia Hulbert
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component.

Authors:  Jing Li; Wenjie You; Difan Zheng; Bei Yan; Xiao Ma; Yunjian Pan; Yang Zhang; Yuan Li; Xuxia Shen; Xinghua Cheng; Yihua Sun; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-24       Impact factor: 4.553

Review 4.  Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.

Authors:  Caroline Wilson; Sarah J Danson
Journal:  Lung Cancer (Auckl)       Date:  2010-05-12

5.  Genetic alterations in lung adenocarcinoma with a micropapillary component.

Authors:  Masashi Furukawa; Shinichi Toyooka; Kouichi Ichimura; Hiromasa Yamamoto; Junichi Soh; Shinsuke Hashida; Mamoru Ouchida; Kazuhiko Shien; Hiroaki Asano; Kazunori Tsukuda; Shinichiro Miyoshi
Journal:  Mol Clin Oncol       Date:  2015-12-02

6.  Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma.

Authors:  Yosuke Togashi; Katsuhiro Masago; Takeshi Kubo; Daichi Fujimoto; Yuichi Sakamori; Hiroki Nagai; Young Hak Kim; Kaori Togashi; Michiaki Mishima
Journal:  Med Oncol       Date:  2012-04-11       Impact factor: 3.064

7.  Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.

Authors:  Hongyan Ying; Xian-Da Yang; Zhao Sun; Xiaohong Ning; Yingyi Wang; Chunmai Bai; Shuchang Chen; Yuzhou Wang
Journal:  Med Oncol       Date:  2014-09-13       Impact factor: 3.064

8.  MicroRNA expression differentiates histology and predicts survival of lung cancer.

Authors:  Maria Teresa Landi; Yingdong Zhao; Melissa Rotunno; Jill Koshiol; Hui Liu; Andrew W Bergen; Maurizia Rubagotti; Alisa M Goldstein; Ilona Linnoila; Francesco M Marincola; Margaret A Tucker; Pier Alberto Bertazzi; Angela C Pesatori; Neil E Caporaso; Lisa M McShane; Ena Wang
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

9.  Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study.

Authors:  Jasmina Obradović; Natasa Djordjević; Natasa Tošic; Jasminka Mrdjanović; Biljana Stanković; Jelena Stanić; Bojan Zarić; Branislav Perin; Sonja Pavlović; Vladimir Jurišić
Journal:  Tumour Biol       Date:  2016-02-05

10.  Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer.

Authors:  Shih-Hsin Hsiao; Sey-En Lin; Yu-Ting Chou; Jinn-Li Wang; Chi-Li Chung; Ming-Chih Yu; Chia-Lang Fang; Hsin-Lun Lee; Ling-Ling Chiang; H Eugene Liu; Cheng-Wen Wu
Journal:  Mol Clin Oncol       Date:  2013-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.